It is also important to note that if CRISPLD2 has antiinflammatory effects – even if it is not a primary inducer of inflammation in COPD – it may still have potential as a broad‐spectrum therapeutic agent in the treatment of lung inflammation in COPD and other lung pathologies. Here, CRISPLD2 is linked to inflammatory response.